Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer In Single-Region Trial Conducted By Akeso In China

Aug. 25 (Reuters) - Summit Therapeutics Inc. SMMT.O:

• Ivonescimab plus chemotherapy demonstrates statistically significant overall survival benefit compared to durvalumab plus chemotherapy in first-line advanced biliary tract cancer in single-region trial conducted by Akeso in China
• Summit Therapeutics - study meets key secondary endpoints of PFS and ORR